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Poster Session I S221cells/kg/Dose). Tumor responses, EBV DNA levels and quantita-
tions of tetramer+, IFNg+ EBV-specific T-cells and EBV CTLp
by limiting dilution analysis (LDA) were monitored. Infusions
were well tolerated; no pt developed GVHD.
Of the 22 pts, 3 died too early to be evaluated (\10 days). Of 6
pts primarily treated with EBV-CTL, 5 (83%) achieved CR, ver-
sus 7/13 (53%) who failed Rituxan. The CR rate was similar in pts
on no immunosuppressives or on Sirolimus or Calcineurin inhib-
itors alone (75% with; 67% without), but was lower for pts on ste-
roids for GVHD or cerebral edema (33%) than for pts off steroids
(69%). Pts with single sites of disease fared better than pts with
multiple sites (75% vs. 42% CR). However, all sites of disease, in-
cluding CNS, were comparably responsive to therapy. CTLp fre-
quencies rose 10-200 fold by 2-3 weeks post infusion in pts
achieving CR and were temporally associated with disease regres-
sion and clearance of EBV DNA. Such increases were not seen in
any pt with PD. EBV CTLs inducing CRs in 8 pts studied lysed
both B95.8 EBVBLCL and spontaneous EBV+ BLCL transform-
ants (S-EBV BLCL) isolated from the pt’s blood or involved tis-
sues; EBV CTL given to 3 non-responders on no
immunosuppression lysed B95.8+ BLCL, but not S-EBVBLCL
of donor origin isolated from the pt.
While EBVCTL can induce durable remissions of EBV lym-
phoma post HSCT, efficacy may be compromised in Rituxan refrac-
tory disease, by ongoing steroid treatment or by failure of the
EBVCTL to recognize the endogenous EBV the pt’s lymphoma.171
IMPROVED T CELL RECOVERY AFTER TRANSPLANTATION OF CD3/CD19
DEPLETED HAPLOIDENTICAL STEM CELL GRAFTS IN PEDIATRIC PA-
TIENTS
Teltschik, H.-M., Feuchtinger, T., Pfeiffer, M., Schumm, M.,
Handgretinger, R., Lang, P. University Children’s Hospital, Tuebingen,
Germany
Profound depletion of T and B cells is a fundamental prerequisite
for haploidentical transplantation and allows tominimizeGvHDde-
spite HLA incompatibility. However, posttransplant recovery of do-
nor derived T cells is delayed after various graft manipulation
procedures and may result in severe infections. Methods to improve
this recovery are of importance. Here we present immune reconsti-
tution data in patients who received CD3/CD19 depleted stem cells
in combination with melphalan based or standard conditioning reg-
imens. 32 patients with ALL(n5 14), AML/MDS n5 17),
CML(n5 1) were included. T- and B-cells were directly depleted
using antiCD3/antiCD19 coatedmagneticmicrobeads and the Clin-
iMACS device. The patients received either TBI or Bu i.v. and
OKT3(n5 9) or a reduced intensity conditioning (‘‘RIC’’: Mel
140 mg/m2, Flud 160 mg/m2, TT 10 mg/kg, OKT3, n5 23).
Absolute numbers of lymphocyte subsets per microliter on day 90
were compared within these both groups and with a historical con-
trol group (patients with leukemias who received CD34 selected
grafts and TBI or Bu based standard conditioning regimen in com-
bination with ATG, n5 28).
CD3 + 4+, CD3 + 8+ and total numbers of CD3+ of patients after
CD3/CD19 depletion were significantly higher in the RIC-group
than in the TBI/Bu-group (mean: 85.83 vs. 38.84; 133.46 vs.
19.69; 270.27 vs. 63.99; p\0.05, t-test).
Comparisonwith thewholeCD34historical group showed a faster
recovery of CD3 + 4+ in patients with CD3/19 depletion and RIC
(104.26 vs. 54.22; p5 0,034) but no significant difference in
CD3 + 8+ and CD3+. Furthermore, subgroups of the CD34 histor-
ical population were compared: patients with CD3/19 depletion
and RIC had a significantly faster recovery of CD3 + 4+, CD3 + 8+
and CD3+ than CD34 patients with TBI (104.26vs. 25.48;
133.46vs. 43.17; 270.27 vs. 65.86; p\0.05) but had no advantage
over CD34 patients with non-TBI conditioning.
Conclusions: the type of graft manipulation appeared to have an
influence on the speed of CD4+ recovery (CD3/19 deple-
tion.CD34 selection). Moreover, the use of TBI had a negative
impact on all T cell subsets: patients with TBI had a slower recov-
ery than patients with non-TBI conditioning, independent from
graft manipulation procedures and probably due to thymic dam-
age. Thus, the use of RIC-protocols in combination with CD3/CD19 depletion may help to speed up the immune recovery after
haploidentical transplantation. Further studies are warranted to
evaluate the risk of relapse.172
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Graft versus Host Disease (GVHD) and infectious complications
are the main cause of morbidity and mortality after allogeneic blood
or marrow transplantation (allo-BMT). Currently, there is no objec-
tive laboratory assay to assess the level of immunereactivity to poten-
tially predict the risk of complications in allo-BMT patients. The
Cylex ImmuKnow assay is approved by theUSFood andDrug Ad-
ministration for detection of cell mediated immunity in immunosup-
pressed individuals. This assay measures immune response to
stimulation by detecting ATP synthesis in CD4 T cells following
phytohemagglutinin (PHA) stimulation. We prospectively studied
PHA-induced ATP release in 20 allo-BMT patients weekly from
day +15 until day +100 post-transplantation. We tested 224 blood
samples with an average of 11.2 per patient (SD 1.8). Patients re-
ceived grafts from matched unrelated (MUD, n5 11 [55%]),
matched related (MRD, n5 8 [40]) and syngeneic donors (n5 1).
Myeloablative and nonmyeloablative conditioning regimens were
used in 13 (65%) and 7 (35%) patients, respectively. 12 patients
(60%) developed GVHD requiring treatment, 2 (10%) developed
GVHD which did not require treatment, and 6 (30%) did not de-
velop any GVHD. Cyclosporine levels (n5 19) did not correlate
with ATP response, nor did the graft composition (CD34+ cells/
kg or the CD3+ cells/kg). Further, we determined that the maximum
ATP level was not a significant predictor of GVHD incidence, nor
was the maximum fold increase over baseline. However, we observed
worse outcomes in patients who had sustained low ATP levels as de-
fined by 3 consecutive measurements of ATP\75 ng/mL.We found
a significant correlation between persistently suppressed ATP levels
and death (p5 0.013). In all patients who died (n5 7), ATP levels
were persistently low and did not recover. In contrast, all 9 patients
who exhibited ATP levels .75ng/ml are alive. Patients who main-
tained an average of .100 ng/ml ATP (mean 235 ng/ML, range
114-402 ng/mL) at monthly intervals did not have GVHD (n5 6)
or require therapy for GVHD (n5 2). Conversely, patients with
ATP levels \100 ng/mL at monthly intervals were treated for
GVHD (mean 84.4 ng/mL, range 24-318ng/mL). Our data suggest
that a persistent immunocompromised state in BMT recipients is as-
sociated with poor outcome. A larger study is warranted to analyze
the utility of the Cylex ImmuKnow assay in BMT patients, which
may enable us to predict outcomes and tailor immunosuppressive
therapy.173
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InHLA-matchedT-cell depleted (TCD)HCT, recipients lacking
class I ligands for donor inhibitory KIR have lower relapse and
higher survival. The ‘‘missing ligand’’ effect on clinical outcome is
likely due to temporary licensing post-transplant of the normally hy-
poresponsiveNK cells expressingKIR for non-selfHLA ligands. Be-
cause the KIR-expressing NK repertoire following HCT can be
affected by T-cells in the allograft, we examined NK functional re-
constitution in recipients of unmodified HCT. We assessed NK
function in 10 patients following unmodified stem cell
S222 Poster Session Itransplantation from an HLA-identical sibling or HLA-compatible
unrelated donor. All patients received a myeloablative regimen and
post-HSCT immunosuppression. Peripheral blood mononuclear
cell (PBMC) samples were collected fromdonors and from recipients
pre-transplant and at days 30, 60 and 200 post-transplant. Using
multiparameter flow cytometric analysis, we evaluated intracellular
IFN-g production among inhibitory KIR-expressing NK subsets
following activation with the class I-deficient 721.221 target cell
line or with 721.221 transfectants expressing the KIR ligands HLA
-Cw3, -Cw4, or -Bw4. Unlicensed NK cells expressing inhibitory
KIR for non-self HLA were hyporesponsive in normal donors. In
comparison, the same NK subsets in patients early post-HCT
(days 15-60) demonstrated robust IFN-g production to target cells
lacking cognate class I ligand (p\0.001). As for TCD HCT, the
temporary licensing effect of nonself-specific NK cells following
T-replete HCT lasted for approximately 100 days, after which NK
cells expressing KIR for non-self HLA returned to a hyporesponsive
state. NK cells expressing inhibitory KIR for self-HLA remained un-
changed in their responsiveness pre- and post-HCT. These findings
contrasted with our previous results in recipients of T-cell depleted
grafts where both licensed and unlicensedNK cells demonstrated in-
creased functional activity early post SCT. KIR expression was gen-
erally delayed following T-replete HCT, with KIR2DL1
particularly lagging in expression beyond 100 days post-HCT.
These results demonstrate that T-cells in the HCT allograft do
not interfere with the temporary licensing effects on NK cells ex-
pressing inhibitory KIR for non-self HLA, which mediate NK allor-
eactivity in HLA-matched HCT.174
IMMUNE RECONSTITUTION (IR) FOLLOWING UNRELATED CORD BLOOD
TRANSPLANTATION (UCBT) IN PEDIATRIC RECIPIENTS: REDUCED TOX-
ICITY CONDITIONING (RTC) IS ASSOCIATED WITH SIMILAR IR BUT A
CONCOMITANT SIGNIFICANT DECREASE IN GRADE II-IV ACUTE GRAFT
VERSUS HOST DISEASE (AGVHD) COMPARED TO MYELOABLATIVE CON-
DITIONING (MAC)
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Background: IR in pediatric transplant recipients appears to take
longer following MAC and UCBT than following matched sib-
ling allogeneic stem cell transplantation (AlloSCT) (Parkman et
al., BBMT, 2006). While RTC prior to AlloSCT is associated
with decreased transplant-related morbidity and mortality com-
pared with MAC, effects of RTC on long-term IR in pediatric
UCBT recipients are unknown (Satwani, Cairo et al., BBMT,
2005).
Objective: To determine the probability of IR following UCBT in
pediatric recipients and risk factors associated with recovery.
Methods: IRwas evaluated in 88 consecutive pediatricUCBT recip-
ients at days +100, +180 and +365. Absolute lymphocyte subsets and
Ig levels were assessed using FACS analysis and ELISA and charac-
terized as normal or low by age-specific norms (Table 1).
Results: 88 pts: median age 6.5 yrs (range 0.25-22); 59% male/41%
female; 56%MAC/44%RTC;HLAmatch 19% 6/6, 28% 5/6, 52%
4/6; 66%malignant/34%non-malignant;medianTNCx107/kg 3.81
(0.9-22.61),medianCD34 x105/kg 2.13 (0.34-9.57).Day 180NKcell
levels were slightly higher in theMAC vs. RTC group (p5 .05); oth-
erwise, lymphocyte subsets and immunoglobulin levels did not differ
significantly between MAC and RTC groups but were similarly de-
layed with respect to CD3, CD4 and CD8. Grade II-IV aGVHD,
ATG/Campath conditioning, viral/fungal infection and TNC/
CD34 dose/kg were not associated withT, B andNK cell reconstitu-
tion.
In 79 evaluable pts, the Kaplan-Meier probability of grade II-IV
aGVHDwas 33.8% (CI95 23.8%-46.5%). In aCox proportional haz-
ards model that included conditioning regimen (MAC vs. RTC), risk(average vs. poor),HLA-matching (4/6 vs. 5-6/6),CMVstatus (donor
neg/recipient neg vs. other) and time period (before 2005 vs. 12/31/
04 onward) to analyze predictors of grade II-IV aGVHD, MAC re-
cipients had a significantly higher risk of grade II-IV aGVHD (HR
5.0, CI95 1.8-14.1, p5 .002) along with those receiving a 4/6 HLA-
matched cord blood unit (HR 3.0, CI95 1.2-7.8, p5 .02). In a similar
Cox model, pts receiving a 4/6 cord blood graft had a significantly
higher risk of chronic GVHD (HR 30.7, CI95 2.2-433.1, p5 .01).
Conclusions: B and NK cell IR were both fairly robust following
UCBT in pediatric pts regardless of conditioning intensity. How-
ever, T cell IR was delayed but unaffected by RTC. Although
RTC was associated with significantly less Grade II-IV aGVHD,
new methods are needed in the future to accelerate T cell IR post-
UCBT.
Table 1. Absolute lymphocyte subset counts and immuno-
globulin levels and percentages of children achieving normal
counts post-UCBT, stratified by conditioning regimen
MAC RTC TotalSubset/
Level,
Date Post-
TransplantMean6 SD
(cells/mL
or mg/dL) N%
ormalMean6 SD
(cells/mL
or mg/dL) N%
ormalMean6 SD
(cells/mL
or mg/dL) N%
ormalCD3 Day
100207.96 232.6 0 261.76 251.1 0 238.26 240.8 0CD3 Day
180425.16 344.5 0 378.56 390.0 0 396.36 365.1 0CD3 Day 3651809.16 1392.9 50 1541.46 1141.1 56 1630.66 1206.8 54CD4 Day
100101.16 83.8 0 136.36 176.5 0 120.96 142.6 0CD4 Day
180271.56 213.7 25 211.26 259.3 8 234.16 239.2 14CD4 Day
365770.16 628.7 50 933.26 597.7 81 878.86 599.6 71CD8 Day
10090.76 180.0 7 101.66 118.3 0 96.86 145.9 3CD8 Day
180137.96 167.1 13 135.56 109.9 0 136.46 130.5 5CD8 Day
365935.66 932.6 50 563.56 426.1 63 687.56 644.4 58CD19 Day
100525.26 571.1 43 649.36 577.8 61 595.06 569.0 53CD19 Day
180
1057.66 678.2 63 778.06 804.8 69 884.56 754.3 67CD19 Day
365916.06 621.7 75 1170.36 585.8 100 1085.56 597.0 92CD56 Day
100255.06 174.0 71 249.46 169.0 83 251.86 168.4 78CD56 Day
180310.06 212.5 75 171.36 83.1 69 224.16 157.2 71CD56 Day
365369.36 178.1 86 255.16 153.0 81 289.86 165.8 83IgG Day
100642.56 278.3 62 649.66 210.5 50 647.06 233.9 54IgG Day
180672.66 367.1 40 623.86 258.1 50 648.26 309.8 45IgG Day
365606.16 298.6 50 728.76 178.8 70 674.26 240.0 61IgM Day
10031.06 26.5 31 30.86 21.1 45 30.96 22.8 40IgM Day
18056.36 45.2 70 57.76 47.4 70 57.06 45.1 70IgM Day
36589.16 43.5 88 88.86 72.6 90 88.96 59.7 89IgA Day
10041.66 51.3 62 124.66 249.9 64 93.76 237.3 63IgA Day
18060.36 64.8 80 61.26 50.0 60 60.86 56.3 70IgA Day
36587.36 84.2 75 77.16 47.9 80 81.66 64.5 78
